A Clinical Study on the Antihypertensive Effects of Arotinolol(Almarl).
10.4070/kcj.1990.20.4.793
- Author:
In Kyung SUNG
;
Byung Moo YOO
;
Jeong Hyun KIM
;
Heon Kil LIM
;
Bang Hun LEE
;
Chung Kyun LEE
- Publication Type:Original Article
- Keywords:
Arotinolol;
Hypertension
- MeSH:
Alkaline Phosphatase;
Blood Glucose;
Blood Pressure;
Cholesterol;
Creatinine;
Fasting;
Heart Rate;
Humans;
Hypertension;
Thorax;
Triglycerides;
Uric Acid
- From:Korean Circulation Journal
1990;20(4):793-799
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Arotinolol, a now alpha and beta bloking agent, was administered orally in 32 hypertensive patients for 8 weeks in order to evaluate the antihypertensive effects and side effects. The doses were from 20mg to 30mg a day. The serum chemistries and chest X-ray were taken before and after Arotinolol administration. The results were as follows; 1) Blood pressure which was measured in sitting, supine and standing position was 176.37+/-4.73/116.54+/-4.34, 170.14+/-5.35/103.12+/-3.67, 156.37+/-7.54/104.31+/-3.34mmHg in control and 144.63+/-2.78/94.41+/-2.87, 146.47+/-5.41/89.12+/-4.34, 140.71+/-4.47/89.73+/-3.71mmHg in the treatment group. The differences between both blood pressure were statistically significant(P<0.001). 2) There was no significant change in pulse rate before and after medication. 3) There was no significant change in the laboratory findings such as CTR, GOT, GPT, alkaline phosphatase, CPK, creatinine, BUN, uric acid, cholesterol, fasting blood sugar and triglyceride before and after treatment. 4) The side effects of arotinolol were observed in 6 of 32 cases(18.7%), which were not required discontinuing the medication or decreasing the dose.
